JP Morgan Chase
CSTL icon

JP Morgan Chase’s Castle Biosciences CSTL Stock Holding History

JP Morgan Chase’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Sell
84,804
-3,967
-4% -$88.4K ﹤0.01% 4152
2026
Q1 		$2.09M Sell
88,771
-1,261
-1% -$41.3K ﹤0.01% 4070
2025
Q4 		$3.5M Buy
90,032
+62,254
+224% +$2.01M ﹤0.01% 3638
2025
Q3 		$633K Buy
27,778
+1,115
+4% +$22.6K ﹤0.01% 4890
2025
Q2 		$544K Sell
26,663
-3,914
-13% -$72.5K ﹤0.01% 4733
2025
Q1 		$612K Sell
30,577
-77,359
-72% -$1.92M ﹤0.01% 4653
2024
Q4 		$2.88M Buy
107,936
+38,527
+56% +$1.17M ﹤0.01% 3870
2024
Q3 		$1.98M Buy
69,409
+43,241
+165% +$1.1M ﹤0.01% 4017
2024
Q2 		$570K Sell
26,168
-49,975
-66% -$1.11M ﹤0.01% 4616
2024
Q1 		$1.69M Buy
76,143
+25,777
+51% +$561K ﹤0.01% 3977
2023
Q4 		$1.09M Sell
50,366
-2,297
-4% -$40.4K ﹤0.01% 4276
2023
Q3 		$889K Buy
52,663
+1,165
+2% +$20.4K ﹤0.01% 4128
2023
Q2 		$707K Buy
51,498
+7,170
+16% +$145K ﹤0.01% 4283
2023
Q1 		$1.01M Buy
44,328
+8,930
+25% +$218K ﹤0.01% 4041
2022
Q4 		$833K Buy
35,398
+2,449
+7% +$56.8K ﹤0.01% 4177
2022
Q3 		$860K Buy
32,949
+2,826
+9% +$79.2K ﹤0.01% 4118
2022
Q2 		$661K Buy
30,123
+5,799
+24% +$135K ﹤0.01% 4382
2022
Q1 		$1.09M Buy
24,324
+754
+3% +$31.2K ﹤0.01% 4196
2021
Q4 		$1.01M Buy
23,570
+1,477
+7% +$77.2K ﹤0.01% 4374
2021
Q3 		$1.47M Buy
22,093
+4,899
+28% +$345K ﹤0.01% 4022
2021
Q2 		$1.26M Sell
17,194
-15,078
-47% -$996K ﹤0.01% 4133
2021
Q1 		$2.21M Buy
32,272
+9,802
+44% +$737K ﹤0.01% 3649
2020
Q4 		$1.51M Buy
22,470
+13,903
+162% +$754K ﹤0.01% 3692
2020
Q3 		$433K Sell
8,567
-1,698
-17% -$75.5K ﹤0.01% 4044
2020
Q2 		$387K Sell
10,265
-2,277
-18% -$77.8K ﹤0.01% 3958
2020
Q1 		$374K Buy
12,542
+10,855
+643% +$328K ﹤0.01% 3964
2019
Q4 		$58K Buy
1,687
+476
+39% +$11.6K ﹤0.01% 5075
2019
Q3 		$22K Buy
+1,211
New +$26.8K ﹤0.01% 5390

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's CSTL Position: Q2 2026 in Review

JP Morgan Chase reduced its Castle Biosciences (CSTL) stake by 4.5% in Q2 2026, selling an estimated $88.4K and leaving 84,804 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4152.

JP Morgan Chase first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $3.5M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • JP Morgan Chase held 84,804 shares of Castle Biosciences worth $2.06M as of Q2 2026.
  • JP Morgan Chase sold 3,967 Castle Biosciences shares in Q2 2026, an estimated $88.4K.
  • Castle Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4152 holding.
  • JP Morgan Chase first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Castle Biosciences position peaked at $3.5M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.